Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05463224
Other study ID # 2022-09-029
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 2, 2023
Est. completion date July 31, 2025

Study information

Verified date November 2023
Source Samsung Medical Center
Contact Myung-Ju Ahn, MD
Phone 82-2-3410-3488
Email silk.ahn@samsung.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to evaluate the efficacy/safety of lazertinib and to explore the resistance mechanism of lazertinib as first-line in patients with NSCLC harboring activating EGFR mutations.


Description:

As the 3rd generation EGFR TKI become a standard treatment option for the 1st line therapy in EGFR mutated patients, necessity for evaluating resistant mechanism to determine the matched subsequent therapeutic option has been highlighted. The idea of understanding the exact resistance mechanism to 1st line 3rd generation EGFR TKI treatment is emphasized based on the observation that resistance mechanism is different based on osimertinib used as 1st line or 2nd line treatment.6,7 Although resistance mechanisms to lazertinib in patients with prior EGFR TKI treatment have been studied, there are no current data available regarding the resistance mechanism after first-line lazertinib treatment. Based on this observation, PI designed this study to elucidate the efficacy/safety of Lazertinib and to explore resistance mechanisms of 1st line lazertinib treatment in NSCLC patients with activating EGFR mutation.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date July 31, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer which is not amenable to treatment with a curative aim (e.g. surgery or radiation). Patients who underwent curative intent surgery or definitive CRT and experience recurrence after 6 months are eligible. - Stage IIIC or IV by AJCC 8th edition - Confirmed EGFR mutations (exon 19 deletion, L858R)(The result from both cell-free DNA or tissue-based DNA from the local test is allowed.) - Age of 19 or more. - Performance status of Eastern Cooperative Oncology Group 0 to 2. - Expected minimum life expectancy of 12 weeks - Adequate organ function. - Available to provide the adequate tissue and blood for the genomic tests- At least 15 unstained slide and 20 cc of blood at baseline (mandatory) and disease progression. - Agreed to perform re-biopsy at the timepoint of disease progression. - At least two weeks after the chemotherapy - Female subjects must either be of non-reproductive potential - Subject willing and able to comply with the protocol - Signed written informed consent Exclusion Criteria: - Previously treatment with any kind of EGFR TKI (Previously chemotherapy treated patients is allowed) - Any concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug. (allowed for participation if investigator decided that previous malignancy is cured and not need for any additional treatment) - Uncontrolled central nervous system metastases- patient with asymptomatic brain metastases or CNS symptom manageable with TKI and evaluated by investigator can be enrolled. - Spinal cord compression, leptomeningeal carcinomatosis - Uncontrolled systemic illness, including uncontrolled hypertension, active bleeding, or active infection - Radiotherapy with a wide field of radiation within 2 weeks or radiotherapy with a limited field of radiation (localized radiotherapy or gamma knife surgery) for palliation within 1 week - Any unresolved toxicities from prior therapy, greater than CTCAE grade 1 - Mean QT interval corrected for heart rate (QTc) = 470 ms - No measurable lesion - Unable to swallow the product due to refractory nausea, vomiting or chornic gastrointestinal disease.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lazertinib group
Lazertinib 240mg, Once, po, daily (1 cycle of 21 days)

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul Gangnamgu

Sponsors (1)

Lead Sponsor Collaborator
Myung-Ju Ahn

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary progression-free survival C1D1 until the date of objective disease progression or death through study completion, an average of 18.0 month
Primary Resistance mechanism analysis The mutation profile of baseline and at the timepoint of resistance will be evaluated using tissue and cfDNA Screening, Discontiunuation Visit
Secondary Objective response rate (ORR) as the percentage of patients with measurable disease with at least one visit response of complete response (CR) or partial response (PR) through study completion, an average of 18.0 month
Secondary Duration of Response (DoR) as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first through study completion, an average of 18.0 month
Secondary Disease control rate (DCR) as the percentage of patients who have a best overall response of CR or PR or stable disease (SD at = 6 weeks, prior to any PD event) through study completion, an average of 18.0 month
Secondary Overall survival (OS) s the time from the date of C1D1 until the date of death due to any cause through study completion, an average of 18.0 month
Secondary intracranial PFS (iPFS) as the time from C1D1 until the date of objective intracranial disease progression or death whichever comes first in patients for the iFAS through study completion, an average of 18.0 month
Secondary intracranial ORR (iORR) as the percentage of patients who have at least 1 CR or PR in intracranial lesion, according to RECIST v1.1 prior to disease progression in patients who have at least one measurable intracranial lesion at baseline through study completion, an average of 18.0 month
Secondary intracranial DCR (iDCR) as the percentage of patients who have a best intracranial overall response of CR or PR or SD in patients who have at least one measurable intracranial lesion at baseline through study completion, an average of 18.0 month
See also
  Status Clinical Trial Phase
Recruiting NCT05821933 - RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC Phase 1/Phase 2
Active, not recruiting NCT03269162 - Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection Phase 3
Recruiting NCT05002270 - JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation Phase 1/Phase 2
Recruiting NCT06315686 - The Dynamic Monitoring of Cerebrospinal Fluid ctDNA Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Recruiting NCT05466149 - Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2
Completed NCT03609918 - Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing
Recruiting NCT06043817 - First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Recruiting NCT05078931 - A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients Phase 2
Not yet recruiting NCT05547737 - Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer
Not yet recruiting NCT05909137 - Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer
Withdrawn NCT05959473 - EGFR_IUO 3.20 Clinical Study Protocol N/A
Not yet recruiting NCT05005468 - A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. Phase 2
Recruiting NCT01690390 - Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease Phase 2
Completed NCT01852578 - Cabazitaxel in Relapsed and Metastatic NSCLC Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Completed NCT00866970 - Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia Phase 2
Completed NCT00702975 - Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy Phase 2